'Uninhibited' price hikes, lobbying and more: Congressional probe gives detailed look into Teva's long run with Copaxone

Although Teva lost exclusivity for its lucrative multiple sclerosis drug Copaxone a while back, the company repeatedly raised prices for years and used aggressive strategies to grow its market and fend off competition, a new congressional report (PDF) finds.